Trusted Resources: People & Places
Healthcare providers, researchers, and advocates
Montefiore Medical Center Comprehensive Thyroid Program
111 East 210th StreetBronx, New York, United States
Phone Web
The highly experienced physicians with the Montefiore Medical Center Comprehensive Thyroid Program diagnose and treat patients with the full spectrum of thyroid disorders from routine nodules to hyperthyroidism, congenital hypothyroidism and complex conditions. Our program is designed to ensure that patients benefit from care that is comprehensive, seamless, coordinated and focused on their needs. Collaboration between Montefiore physicians and specialists is at the heart of our Comprehensive Thyroid Program. We use a team approach to coordinate every aspect of patient care from the initial evaluation to treatment and meticulous follow-up monitoring.
The program’s uniquely centralized and coordinated approach ensures that we can move as swiftly and efficiently as possible to diagnose conditions and formulate the most definitive, personalized and productive treatment plan possible.
Montefiore is one of only a handful of medical centers in the New York metropolitan area and the only hospital in the Bronx to offer these state-of-the-art services for the full spectrum of thyroid disorders in such an integrated, inclusive fashion. This approach ensures optimal results for our patients.
myBinderRelated Content
-
Does Treatment of Graves’ Disease Modify The Long-Term Course of Graves’ Orbitopathy?Introduction: Graves’ orbitopathy (GO...
-
Frequency of Flame Sensor Activation in Public Places After Administration of Radioactive Iodine To Treat GravesR...Objective: Ultraviolet (UV)-perception-...
-
New York-Presbyterian Brooklyn Methodist HospitalA voluntary, acute-care teaching hospita...
-
PREGO (Presentation of Graves’ Orbitopathy) Study: Changes in Referral Patterns to European Group On Graves...Background/Aims: The epidemiology of Gr...
-
Prospective, Systematically Recorded Mycophenolate Safety Data in Graves’ OrbitopathyContext: The antiproliferative mechanis...
-
Kevin Thomas Brumund, MDKevin Brumund is Associate Professor in ...
-
New Data from Phase 3 Teprotumumab Trial Shows Dramatic Reduction in Proptosis, or Eye Bulging, the Main Cause of Mo...Horizon Pharma plc today announced that ...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Google